Follicular Lymphoma

Matthew Matasar, MD, discusses the development of mosunetuzumab and how it is a positive step forward in the field of follicular lymphoma treatment.

An analysis of Medicare patients with follicular lymphoma revealed which characteristics correlated with overall survival.

In the pivotal phase 2 GO29781 study, the objective response rate and response durability was high, leading to the FDA approval of mosunetuzumab for the treatment of relapsed or refractory follicular lymphoma.

Phase 2 study results show the durability of response associated with mosunetuzumab in patients with relapsed or refractory follicular lymphoma.

Christopher J. Melani, MD, discusses the combination regimen from the ViPOR study evaluating patients with aggressive lymphomas.

Closing out their discussion on bispecific antibody therapies, Matthew Matasar, MD and Laurie Sehn, MD, consider ongoing clinical trials and real-world use of these novel agents.

Experts Matthew Matasar, MD and Laurie Sehn, MD, nuance the adverse event profiles of bispecific antibody therapies and consider how these will help inform treatment decisionmaking.

Expert perspectives on the advent of bispecific antibody therapy in relapsed/refractory follicular lymphoma, centered on data and experience with several novel agents.

High objective response and complete response rates observed with mosunetuzumab in patients with relapsed/refractory follicular lymphoma.

Sarah C. Rutherford, MD, discussed how findings from her research could impact the current guidelines for follicular lymphoma.

The FDA has granted priority review to an approval application for mosunetuzumab for the treatment of patients with relapsed or refractory follicular lymphoma.

The European Commission has granted a conditional marketing authorization to mosunetuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 prior systemic therapies

The addition of zanubrutinib to obinutuzumab in patients with relapsed/refractory follicular lymphoma demonstrated improved overall response rates, progression-free survival, and overall survival.

Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.

The FDA has granted accelerated approval to tisagenlecleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after receiving 2 or more lines of systemic therapy.

Match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in the ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar outcomes in regard to efficacy between the 2 cellular therapies.

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Epcoritamab had been granted orphan drug designation by the FDA for the treatment of follicular lymphoma and is being studied in a phase 1/2 clinical trial.

“It's an exciting time with all the novel agent development in relapsed indolent lymphoma,” according to Brad S. Kahl, MD.

Without confirmed clinical benefit in follicular lymphoma and small lymphocytic leukemia, idelalisib's indications for these malignancies were withdrawn from the United States market.

The investigational agent glofitamab produced high responder rates in combination with obinutuzumab in multiple relapsed or refractory follicular lymphoma.

Based on findings from extended follow-up analysis of the phase 2 ELARA study, tisagenlecleucel is a beneficial treatment for patients with relapsed or refractory follicular lymphoma.

Monsunetuzumab induced deep and durable remission in patients with heavily pretreated follicular lymphoma.

The combination of obinutuzumab with polatuzumab vedotin, or lenalidomide may be a solution for the toxicity sometimes observed with chimeric antigen receptor T cells in patients with follicular lymphoma.

The post-marketing requirements for duvelisib are no longer necessary, according to the FDA, and the agent has been withdrawn from the United States market for the treatment of patients with relapsed or refractory follicular lymphoma.